BioCentury
ARTICLE | Clinical News

Ocugen reports Phase II data for dry eye disease candidate

April 13, 2018 5:59 PM UTC

Ocugen Inc. (Malvern, Pa.) reported data from a Phase II trial showing that dry eye disease candidate OCU310 met the primary endpoint of tolerability over a 12-week period. The company said the trial was not powered to show statistical significance for efficacy, but that twice-daily OCU310 showed "meaningful improvements" on endpoints related to the signs and symptoms of dry eye disease, including Symptom Assessment Questionnaire in Dry Eye (SANDE) scores and conjunctival and corneal staining with lissamine green, compared with placebo.

Ocugen plans to present full data at an upcoming meeting. The double-blind, U.S. trial enrolled about 90 patients with dry eye disease...

BCIQ Company Profiles

Ocugen Inc.